Skip to main content
Fig. 3 | BMC Psychiatry

Fig. 3

From: Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia

Fig. 3

Healthcare resource utilization for PP1M and OAA IPT-weighted cohorts during the 12-month follow-up. CI = confidence interval; IPT = inverse probability of treatment; OAA = oral atypical antipsychotics; PP1M = once-monthly paliperidone palmitate; MMCD = mean monthly cost difference. * indicates p-value <0.05. 1All Poisson models included a binary indicator for the treatment received at the index date. 2Based on bootstrap results (B = 499)

Back to article page